Boston Omaha Corporation Class A Common Stock BOC 深 滬
等待開盤 10-02 09:30:00 美东时间
13.20
+0.120
+0.92%
華盛通- 最 高13.25
- 今 開13.02
- 成交量 15.57万股
- 最 低 12.93
- 昨 收 13.08
- 總市值 4.15亿
- 52周最高 16.20
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 12.27
- 委 比 21.74%
- 總股本 3145.34万
- 歷史最高 49.92
- 量 比 1.31
- 振 幅 2.45%
- 歷史最低 12.15
- 每 手 1
- 風險率 0.72%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Entero Therapeutics Acquires GRID AI; GRID Shareholders To Own 82.5% Of ENTO; No Financial Terms Disclosed
Transaction positions ENTO in the high-growth AI energy-infrastructure market, amid a surge of multi-billion-dollar hyperscaler spending on data centers, and rapid growth in behind-the-meter energy storage solutionsBOCA
今天 04:07
Omega Healthcare Named UiPath AI25 Award Winner
Company recognized as one of the 25 most innovative UiPath customers leveraging agentic automation BOCA RATON, Fla., Oct. 1, 2025 /PRNewswire/ -- Omega Healthcare today announced it has been...
10-01 23:08
AbbVie Announces UK Pricing Strategy for ELAHERE® (mirvetuximab soravtansine-gynx)
The list price will be consistent with the United States to reflect the value of the innovation AbbVie is committed to ensuring that developed nations fully recognize the value of our medici...
09-29 21:00
Chaoju Eye Care Expands Investment in BOC Wealth Management Products
Chaoju Eye Care Holdings Ltd. ( ($HK:2219) ) has provided an announcement. Chao...
09-26 21:39
U.S. FDA approves Inluriyo (imlunestrant) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer
An estimated 50% of patients with ER+, HER2– metastatic breast cancer will develop an ESR1 mutation during or after exposure to an aromatase inhibitor In the Phase 3 EMBER-3 trial, Inluriyo ...
09-26 02:01
复宏汉霖HLX22治疗胃癌的头对头III期临床完成阿根廷首例患者给药
内容来源：复宏汉霖 2025年9月23日，复宏汉霖宣布，公司新表位HER2单抗HLX22头对头对比一线标准疗法（曲妥珠单抗+化疗±帕博利珠单抗）的国际多中心I...
09-23 20:21
DeFi Development Corp. Announces Strategic Collaboration With ZeroStack in Treasury Accelerator Deal
BOCA RATON, FL , Sept. 22, 2025 (GLOBE NEWSWIRE) -- DeFi Developmen...
09-22 17:00
潜在同类最优PD-L1 ADC全球开发再提速，复宏汉霖HLX43完成澳大利亚首例...
内容来源：复宏汉霖 目前，HLX43已累计在全球入组400+例患者，其中NSCLC患者超过170例 继中、美之后，HLX43于澳大利亚完成NSCLC国际多中心...
09-19 18:47
How To Trade SPY And Top Tech Stocks Using Technical Analysis
Good Morning Traders! Today’s economic calendar launches with a packed schedul...
09-17 20:47
RedHill Biopharma Announces First Half 2025 Financial Results and Operational Highlights
Extensive strategic, financial and operational overhaul has reshaped and refocused our business; Strong progress on multiple fronts Commercial and R&D Highlights: Recruitment initiated in th...
09-05 19:00
